Compare Ginkgo Bioworks Holdings Inc (DNA) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Rivian (RIVN) trades at $16.39, up 2.44% today, showing bullish technical signals with recent price momentum. The company continues to narrow losses, with Q2 2026 EPS beating expectations at -$0.47 versus -$0.66 expected. Revenue growth is steady, reaching $5.39B in 2025, while cash burn remains a key focus as the R2 vehicle ramp-up progresses.

Outlook is cautiously optimistic with analyst consensus price target of $18.70 offering potential upside. Key opportunities include R2 demand and margin improvements, but risks from high cash burn and competitive pressures persist. Execution on profitability targets will be critical for sustained stock appreciation.